FIELD: drugs.
SUBSTANCE: invention relates to a one-pot method for producing amorphous form 4-[4- [4- [4 - [[(3R, 5R)-5- (2,4-difluorophenyl) tetrahydro-5 (1H-1,2,4-triazole- 1-ylmethyl) -3-furanyl] methoxy] phenyl]-1-piperazinyl]phenyl]-2-[(1S,2S)-1-ethyl-2-hydroxypropyl]-2,4-dihydro-3H-1, 2,4-triazol-3-one of formula (IV) (posaconazole), which includes a) treatment of 4-(4- (4- (4 - (((3R, 5R)-5-((1H-1,2,4-triazol-1-yl)methyl)-5-(2,4-difluorophenyl)tetrahydrofuran-3-yl) methoxy) phenyl) piperazin-1-yl)phenyl)-1-((2S,3S)-2-(benzyloxy)pentan-3-yl)-1H-1,2,4-triazole-5(4H)-one
of formula (III) with concentrated hydrochloric acid and stirring the reaction mixture at a temperature55-70°C, b) cooling the reaction mixture and introducing a halogenated hydrocarbon solvent, c) separation of layers, d) introducing a halogenated hydrocarbon solvent into the aqueous layer and adjusting the pH to 8-12, e) partial concentration of the organic layer and the possible introduction into the reaction mixture of a solvent - aliphatic ketone, f) mixing the reaction mixture of Stage e) and an aliphatic hydrocarbon solvent at a temperature 10-25°C and g) filtration and optional washing with an aliphatic hydrocarbon solvent to obtain an amorphous compound of formula IV, wherein 4-(4-(4-(4-(((3R, 5R)-5-((1H-1,2,4-triazole-1-yl)methyl)-5- (2,4-difluorophenyl) tetrahydrofuran-3-yl) methoxy) phenyl) piperazin-1yl) phenyl)-1- ((2S, 3S) -2- (benzyloxy) pentan-3-yl )-1H-1,2,4-triazol-5 (4H)-one of formula (III) is crystalline B-3 form, which is characterized by the X-ray diffractogram shown in Fig. 3. The invention also relates to crystalline form B-3 4-(4-(4-(4-(((3R, 5R)-5-((1H-1,2,4-triazol-1-yl) methyl)-5- (2,4-difluorophenyl) tetrahydrofuran-3-yl) methoxy) phenyl) piperazin-1-yl) phenyl)-1-((2S, 3S)-2-(benzyloxy) pentan-3-yl)-1H-1, 2,4-triazol-5 (4H)-one of formula (III), which is an intermediate for the preparation of amorphous posaconazole, and a method for its preparation.
EFFECT: effective method for amorphous posaconazole preparation.
5 cl, 3 tbl, 7 dwg, 9 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF PRODUCING VORICONAZOLE | 2008 |
|
RU2434009C1 |
DERIVATIVES OF CYCLOHEXANE OR TETRAHYDROPYRANE OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, OR HYDRATES, OR SOLVATES OF THESE COMPOUNDS, OR THEIR SALTS, INTERMEDIATE COMPOUNDS FOR THEIR SYNTHESIS AND FUNGICIDE AGENT | 1992 |
|
RU2084439C1 |
METHOD OF SYNTHESIS OF TRIAZOLES, ULTIMATE AND INTERMEDIATE COMPOUNDS OF METHOD | 1996 |
|
RU2156760C2 |
NEW PHOSPHORAMIDATE NUCLEOSIDE DERIVATIVES AND APPLICATION THEREOF | 2014 |
|
RU2621709C2 |
METHOD FOR PREPARING VORICONAZOLE AND ITS ANALOGUES | 2013 |
|
RU2619928C2 |
AZOLE COMPOUNDS, METHOD OF THEIR SYNTHESIS, ANTIFUNGAL PHARMACEUTICAL COMPOSITION AND METHOD OF TREATMENT OF FUNGAL INFECTION | 1998 |
|
RU2189982C2 |
N-(1-(1-BENZYL-4-PHENYL-1H-IMIDAZOL-2-YL)-2,2-DIMETHYLPROPYL)-BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS KINESIN SPINDLE PROTEIN (KSP) INHIBITORS FOR TREATING CANCER | 2005 |
|
RU2427572C2 |
NEW CRYSTALLINE FORM OF 2-{3-[2-(1-{[3,5-BIS(DIFLUOROMETHYL)-1H-PYRAZOL-1-YL]ACETYL}PIPERIDIN-4-YL)-1,3-THIAZOL-4-YL]-4,5-DIHYDRO-1,2-OXAZOL-5-YL}-3-CHLOROPHENYLMETHANE SULPHONATE | 2014 |
|
RU2691948C2 |
COMBINED TREATMENT BY A TOLL-LIKE RECEPTOR (TLR7) AGONIST AND A HEPATITIS B VIRUS CAPSID ASSEMBLY INHIBITOR | 2016 |
|
RU2718917C2 |
SYNTHETIC INTERMEDIATE COMPOUND 1-(2-DESOXY-2-FLUORO-4-THIO-β-D-ARABINOFURANOSYL)CYTOSINE, SYNTHETIC INTERMEDIATE THIONUCLEOSIDES COMPOUND AND METHOD FOR THEIR PRODUCTION | 2013 |
|
RU2633355C2 |
Authors
Dates
2021-07-05—Published
2016-09-22—Filed